SEARCH BY
| Category | Company |
|---|---|
| Founded | 2004 |
| Sector | Life Science |
| Employees | 65 |
| Revenue | 9M CHF (2023) |
Evolva is a provider of biosynthetic and evolutionary technologies to create and optimize small molecule compounds and their production routes. Evolva Holding was incorporated in 2004 and is based in Reinach, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Chemicals M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2014 M&A | 2 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-07-31 |
Prosarix
Cambridge, United Kingdom Prosarix Ltd. is a biotechnology company. Prosarix develops computational products for the biotech and pharmaceutical sectors. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-12-17 |
Evolva Holding - EV-035
Switzerland EV-035 is a series of novel small molecule broad spectrum antibiotics of the 4-oxoquinolizine class and targets bacterial type IIa topoisomerase. |
Sell | - |